Cardiovascular magnetic resonance (CMR) imaging is useful to identify systolic dysfunction, particularly when echocardiographic imaging is not acceptable because of poor acoustic windows or when left ventricular ejection fraction (LVEF) is inconclusive by other modalities and an accurate LVEF measurement is needed. Of particular advantage in cardio-oncology is CMR's capability to perform tissue characterization to noninvasively identify changes in pathologic conditions related to cancer therapy or to discriminate causes of disease that may confound presentation in cardio-oncology patients. For these reasons, there is an increasing use of CMR in the screening and surveillance of cardio-oncology patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200142 | PMC |
| http://dx.doi.org/10.1016/j.ccl.2019.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left atrial appendage velocity, association with inflammatory indices in non-valvular atrial fibrillation patients.
Future Cardiol
January 2025
Echocardiography research Center, Rajaie cardiovascular medical and research Center, Iran University of Medical Science, Tehran, Iran.
Introduction: Decreased left atrial appendage emptying velocity (LAAV) is a marker for thrombus formation. This study evaluates the association between LAAV and inflammatory indices in non-valvular atrial fibrillation (AF) patients.
Methods: The study population was 1428 patients with AF, 875 of whom enrolled.
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 - metastatic breast cancer.
Cardiooncology
January 2025
Thalheimer Center for Cardio-Oncology, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Background: Cardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast cancer. However, limited data are available regarding their prevalence in patients with HR + /HER2- metastatic breast cancer (mBC). We evaluated the prevalence of CV comorbidities, the use of concurrent medications with risk of QTc prolongation, and treatment patterns in patients with newly diagnosed HR + /HER2 - mBC.
View Article and Find Full Text PDFPrediction of Radiation Therapy Induced Cardiovascular Toxicity from Pretreatment CT Images in Patients with Thoracic Malignancy via an Optimal Biomarker Approach.
Acad Radiol
January 2025
Medical Image Processing Group, 602 Goddard building, 3710 Hamilton Walk, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 (M.L., M.A., J.K.U., Y.T., C.W., N.P., S.M., D.A.T.). Electronic address:
Rationale And Objectives: Cardiovascular toxicity is a well-known complication of thoracic radiation therapy (RT), leading to increased morbidity and mortality, but existing techniques to predict cardiovascular toxicity have limitations. Predictive biomarkers of cardiovascular toxicity may help to maximize patient outcomes.
Methods: The machine learning optimal biomarker (OBM) method was employed to predict development of cardiotoxicity (based on serial echocardiographic measurements of left ventricular ejection fraction and longitudinal strain) from computed tomography (CT) images in patients with thoracic malignancy undergoing RT.
Emerging toxicities in oncology.
Curr Opin Oncol
January 2025
Centre George François Leclerc -1, rue Professeur Marion-21079, Dijon, Cedex, France.
Purpose Of Review: New anticancer drugs often are associated with improved results, such as objective response and disease-free survival. But with these new drugs, patients, caregivers and medical oncologist have to face new toxicities, quite different from the side effects of conventional chemotherapy. The aim of this review is to share the actual knowledge about these new toxicities.
View Article and Find Full Text PDFCardiovascular Disease and Other Competing Causes of Death in Older Kidney Cancer Patients.
Rev Cardiovasc Med
January 2025
Department of Endocrinology, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, Guangdong, China.
Background: To study the risk of cardiovascular disease (CVD) and other competing causes of death in older kidney cancer patients.
Methods: Data on older patients (aged 65 and above) diagnosed with kidney cancer between 1975 and 2018 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We delved into the distribution of CVD and other competing causes of death across the entire cohort and in various patient subgroups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!